|
In my opinion, (and, as always, I speak only for myself) I would agree that in a head to head competition with "Open Logician" that VistA-Office EHR would lose. That is if all you were comparing was functionality. As a system for the physician's office, Logician is a more mature offering, no question. VistA-Office EHR is only in the embryonic stage. However, if you were to compare them in "open source" market and all that implies and entails, VistA-Office EHR would be the clear winner. To the best of my knowledge, Logician does not have a rabid (and I mean that only in the nicest sense!), international community of developers or an organized community of cooperating vendors who can supply professional services, with all working in concert to promote, support and enhance the application.
Frankly, I'm not sure that VistA has all that yet either and therein lies the challenge and the opportunity! Yes, the serious discussions have to start, but, the VistA community doesn't need a survival strategy, it needs a growth strategy. This will be big. There are roughly 400,000 physicians in the US. If we achieve 1% market penetration...
Mike
>>> [EMAIL PROTECTED] 10/15/2004 11:30:09 AM >>> This is GREAT news! And the Health IT Strategist article, together with the VistA Office release, are "shots heard 'round the world" signaling VistA's long term viability.
Or are they?
Before you "pop the cork" I think you should consider another, very probable (based on my 16 years of experience IT products and services) possibility.
The "we're there" case is really only viable to the extent that VistA Office will be the only "industrial strength" Open Source (i.e., free) EHR software available to community-based physicians. What happens when that changes? How does VistA fare in head-to-head competition with, say, "Open Logician"? My background says VistA loses, big time. On every single front that matter from a market viability perspective.
I won't rain on your parade anymore here except to say that unless the VistA community addresses the marketability issues that have, more than once, been pointed out here, the recent HHS initiatives regarding VistA are not "21 gun salutes." They're shots to the head. I think you need to begin a serious discussion of survival strategy.
Best regards,
Bill
| |||||||||
<<image/gif>>
